Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026

HomeCompaniesSectorsCalendarLast night
Screens
WarningsPrice and conditionThen and nowSize bandsCeased filers
Tools
Time machinePoint in timeData exportsRun logForecast logEDGAR company search
Method
MethodCoverageAbout
Altimmune, Inc.ALT · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $279.9M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, thin data, degenerate inputs · fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Mar 6, 2026217 days before the rescan; every figure keyed to the SEC receipt date
Last close$2.602026-10-08; market equity $505.7M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$4$6NovDecJanFebMarAprMayJunJulAugSepOct$2.60
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2012nonen/aQ2
Mar 21, 2017nonen/aQ3
Apr 21, 2018nonen/aQ2
Mar 21, 2021nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 6, 2026; the document on sec.gov.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), alcohol use disorder (“AUD”) and alcohol-associated liver disease (“ALD”). We may also pursue additional indications for pemvidutide that leverage its differentiated clinical profile. Except where the context indicates otherwise, references to “we,” “us,” “our,” “Altimmune”, or the “Company” refer to the company and its subsidiaries.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 68.9%[3-4]
Thin data. 6 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]
Fortress balance sheet. cash minus debt is 9,473,000 USD; Altman Z is not used[5-6]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 41.4
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
prior invested-capital observation is 2557 days earlier
Accruals ratio(9.8%)[1,7-9](6.6%)41.48112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 21.4
Twelve-month failure probability0.04%0.07%24.72482026-06-30
Altman Z double-prime0.63[1,10-15](0.31)34.87562025-12-31
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current ratio18.55x[10-11]2.96x4.88392025-12-31
Growth and financing, sleeve percentile 55.3
Revenue growth, three-year compoundnot computable10.0%
current value must be positive and the base must exceed $100,000
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 13
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years10.6%[1,9,16-17]2.1%30.97042025-12-31
Net share issuance, one year68.9%[3-4]2.5%79.86342026-02-27

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(17.5%)8.0%32hotter than 32 of 100 peers
Distance from 52-week high(57.9%)(31.4%)19closer to its high than 19 of 100 peers
EBIT to enterprise value(19.8%)(1.5%)23pricier than 77 of 100 peers
Free cash flow yield(13.4%)(1.0%)28pricier than 72 of 100 peers
Book value to price0.940.2886pricier than 14 of 100 peers
Sales to price0.000.311pricier than 99 of 100 peers
Composite equity issuance, five years165.6%20.3%86more equity-funded than 86 of 100 peers
Relative strength against the sector, log excess return(0.40)(0.14)32ahead of 32 of 100 peers

Inputs: market equity $505.7M; EBIT -$94.5M; free cash flow -$67.5M; book equity $474.2M; sales $41,000; debt $34.7M; cash $63.0M[18].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(63.2%)✗ fail[7,9]
Operating cash flow above zero-$67.5M✗ fail[8]
Return on assets improved(18.1 pts)✗ fail[7,9,16,19]
Operating cash flow exceeds net income$20.6M✓ pass[7-8]
Long-term leverage felln/a[1,9,16,20]
Current ratio improved543.8 pts✓ pass[10-11,21-22]
No new shares issued68.9%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improved0.0 pts✓ pass[2,9,16,23]
Cash, filings, liquidity
Cash and equivalents$63.0M[24]
Operating cash flow, four quarters-$76.5M[8,24-28]
Months of runway9.9
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing58
10-Q received Aug 12, 2026
Median daily dollar volume$10.9M
63 sessions
Days since newest grade input217

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$279.9M2025-12-312026-03-0610-Kfiling · viewer · series
2revenueus-gaap:Revenues$41,0002025-12-312026-03-0610-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding130,069,9832026-02-272026-03-0610-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding77,013,6582025-02-242025-02-2710-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$43.8M2025-12-312026-03-0610-Kfiling · viewer · series
6total debtus-gaap:LongTermDebt$34.3M2025-12-312026-03-0610-Kfiling · viewer · series
7net incomeus-gaap:NetIncomeLoss-$88.1M2025-12-312026-03-0610-Kfiling · viewer · series
8operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$67.5M2025-12-312026-03-0610-Kfiling · viewer · series
9assetsus-gaap:Assets$139.3M2024-12-312026-03-0610-Kfiling · viewer · series
10current assetsus-gaap:AssetsCurrent$278.2M2025-12-312026-03-0610-Kfiling · viewer · series
11current liabilitiesus-gaap:LiabilitiesCurrent$15.0M2025-12-312026-03-0610-Kfiling · viewer · series
12retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$649.5M2025-12-312026-03-0610-Kfiling · viewer · series
13operating incomeus-gaap:OperatingIncomeLoss-$94.5M2025-12-312026-03-0610-Kfiling · viewer · series
14book equityus-gaap:StockholdersEquity$224.9M2025-12-312026-03-0610-Kfiling · viewer · series
15liabilitiesus-gaap:Liabilities$55.0M2025-12-312026-03-0610-Kfiling · viewer · series
16assetsus-gaap:Assets$210.6M2023-12-312025-02-2710-Kfiling · viewer · series
17assetsus-gaap:Assets$206.9M2022-12-312024-03-2710-Kfiling · viewer · series
18shares outstandingdei:EntityCommonStockSharesOutstanding194,517,7012026-08-072026-08-1210-Qfiling · viewer · series
19net incomeus-gaap:NetIncomeLoss-$95.1M2024-12-312026-03-0610-Kfiling · viewer · series
20long term debtus-gaap:LongTermDebtNoncurrent$34.3M2025-12-312026-03-0610-Kfiling · viewer · series
21current assetsus-gaap:AssetsCurrent$137.3M2024-12-312026-03-0610-Kfiling · viewer · series
22current liabilitiesus-gaap:LiabilitiesCurrent$10.5M2024-12-312026-03-0610-Kfiling · viewer · series
23revenueus-gaap:Revenues$20,0002024-12-312026-03-0610-Kfiling · viewer · series
24cashus-gaap:CashAndCashEquivalentsAtCarryingValue$63.0M2026-06-302026-08-1210-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$45.2M2026-06-302026-08-1210-Qfiling · viewer · series
26operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$20.9M2026-03-312026-05-1310-Qfiling · viewer · series
27operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$48.1M2025-09-302025-11-0610-Qfiling · viewer · series
28operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$36.2M2025-06-302026-08-1210-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.

Informational and educational only. Not investment advice. SEC and market data may contain errors.

If you have any comments about this page, the methodology and every line of code that produced it are in the public repository. However, due to the limited number of personnel, we are unable to provide a direct response.

Pages
Home · Companies · Sectors · Calendar · Last night
Screens
Warnings · Price and condition · Then and now · Size bands · Ceased filers
Tools
Time machine · Point in time · Data exports · Run log · Forecast log · EDGAR company search
Method
Method · Coverage · About
Source
GitHub · ezrakruger.cc
Photographs from Wikimedia Commons

bull: Raphael Schön from Vienna, Austria, CC BY 2.0; bear: U. S. Fish and Wildlife Service - Northeast Region, Public domain; elk: Oregon Department of Fish & Wildlife, Public domain; tortoise: NPS, Public domain; sloth: Charles J. Sharp, CC BY-SA 3.0; fox: Cp9asngf, CC BY-SA 4.0; sector-business_equipment: Sangitiana Fararano, CC BY-SA 2.0; sector-healthcare: User:Squidonius, myself, and User:Beliason (assumed)., CC BY-SA 4.0; sector-manufacturing: unknown, CC BY-SA 2.0; sector-shops: Wilfredor, CC BY-SA 4.0; sector-consumer_nondurables: Nielsoncaetanosalmeron, CC BY 4.0; sector-utilities: Lijovklm, CC BY-SA 4.0; sector-consumer_durables: Stilfehler, CC BY-SA 4.0; sector-chemicals: PEO ACWA, CC BY 2.0; sector-energy: Arne Hückelheim, CC BY-SA 3.0; sector-telecom: Wikideas1, CC0; sector-other: Downtowngal, CC BY-SA 4.0.

Updated Oct 9, 2026